Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Licensing Agreement for "Linzagolix" with Searchlight Pharma in Canada
Notice Regarding Sale of Investment Securities (Result)
Licensing Agreement with Viridian Therapeutics for "Veligrotug" and "VRDN-003" in Treatment of Thyroid Eye Disease
Consolidated Financial Results for the Three Months Ended June 30, 2025 [Japanese GAAP]
Notice Concerning Revisions to Financial Results Forecast and Recording of Extraordinary Income
Supplementary Explanatory Materials on Financial Results for the Three Months Ended June 30, 2025
KISSEI PHARMA, Ordinary Profit Forecast for the Fiscal Year Revised Downward to a Loss
Notice Regarding Completion of Disposal of Treasury Stocks as Restricted Stock for Members of the Board and Corporate Officers
New Launch of TAVALISSE for Chronic Idiopathic Thrombocytopenic Purpura Treatment in South Korea
Notice Concerning Disposal of Treasury Shares as Restricted Stock for Members of the Board and Corporate Officers
Financial Briefing for the Fiscal Year Ended March 31, 2025 (Fiscal 2024)
Notice Concerning the Results of the Acquisition of Treasury Shares, Through Off-Auction Treasury Share Repurchase Trading System
The New Five-Years Medium-term Management Plan “Beyond 80”
Consolidated Financial Results for the Fiscal Year Ended March 31, 2025 [Japanese GAAP]
Supplementary Explanatory Materials on Financial Results for the Fiscal Year Ended March 31, 2025
Notice Concerning Dividends of Surplus (Increase in Dividend)
Notice on the Acquisition of Treasury Shares, the Acquisition of Treasury Shares Through Off-Auction Own Share Repurchase Trading
Notice Concerning Revision of the Executive Compensation System
KISSEI PHARMA, Last Fiscal Year's Ordinary Profit Unexpectedly Increases, 6% Increase in Ordinary Profit for The Current Fiscal Year, Increased Previous Year's Dividend by 10 yen, This Fiscal Year to Increase Dividend by 20 yen
Submission of New Drug Application for GnRH Antagonist "Linzagolix" Indicated for Uterine Fibroids, in Japan